Publication
Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.
Authors not recorded
Oncogene2002PMID 12476305stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerAcute Myeloid Leukemiacivic_curation1.00
- drugImatinibcivic_curation1.00
- geneABL1civic_curation1.00
- variantABL1 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (2)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 12476305
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ABL1 Fusion2 | ||||||||
| Imatinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID259Treatment of Philadelphia chromosome positive leukemias with imatinib results in high rates of complete remission in patients with CML. PMID 12476305 · Nimmanapalli et al., 2002 · Open in CIViC | civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | accepted | EID232BCR-ABL fusions have been found to contribute to imatinib resistance in AML cell lines. PMID 12476305 · Nimmanapalli et al., 2002 · Open in CIViC | civic |